Patents Examined by Mary Lyons
-
Patent number: 9150622Abstract: Rhodococcus equi (R.equi) has been determined to have a major adhesion factor encoded by a rpl pathogenicity island which enables host colonisation, wherein the rpl pathogenicity islandis absent from non-pathogenic Rhodococcus species. Further, the proteins (Rpl) encoded by the rpl pathogenicity islandhave been determined to be major immunodominant antigens. There is provided a novel diagnostic marker and vaccine candidate for R. equi in horses and other susceptible species.Type: GrantFiled: November 11, 2010Date of Patent: October 6, 2015Assignee: UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGHInventor: Jose Antonio Vazquez Boland
-
Patent number: 9145574Abstract: The subject invention provides point-of-care assays for assessing the topographical distribution of microbial biofilm and/or specific microorganisms in wounds.Type: GrantFiled: April 26, 2010Date of Patent: September 29, 2015Assignee: University of Florida Research Foundation, Inc.Inventors: Gregory S. Schultz, Priscilla Lorraine Phillips, Edith Marion Sampson
-
Patent number: 9119802Abstract: The present disclosure relates to methods and compositions for the treatment and prevention of microbial infections and for the enhancement of resistance to infection. The disclosure includes administration of an effective amount of an E. coli LpfA antigen to enhance the immune system to prevent infections that cause, e.g., inflammatory bowel diseases, bovine mastitis and metritis. The disclosure also includes methods for diagnosing microbial infection and conditions associated with microbial infection by detecting an E. coli LpfA polypeptide or nucleic acid.Type: GrantFiled: May 4, 2010Date of Patent: September 1, 2015Assignee: Cornell UniversityInventors: Kenneth W. Simpson, Belgin Dogan
-
Patent number: 9090676Abstract: The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ. ID. No. 1, whereby such region is defined by (a) amino acid positions 150 to 200 of the amino acid sequence according to SEQ. ID. No. 1, or (b) amino acid positions 410 to 480 of the amino acid sequence according to SEQ. ID. No. 1, and whereby the polypeptide is suitable to elicit an immune response which is capable of inhibiting the catalytic activity of HPGGT.Type: GrantFiled: October 19, 2007Date of Patent: July 28, 2015Assignee: IMEVAX GMBHInventors: Markus Gerhard, Christian Schmees, Christian Prinz
-
Patent number: 9074227Abstract: A helical fine structure of the present invention is characterized by including: a phytoplankton having a helical shape and selected from a group of cyanobacteria called Spirulina; and a surface modification layer formed on the phytoplankton. The surface modification layer includes at least one metal plating layer. Thereby, the helical fine structure can be utilized as an electric-wave shield or an absorber. Moreover, a method for producing the helical fine structure is characterized in that a prestep of a step of forming the surface modification layer on the phytoplankton having a helical shape includes a washing step with an organic solvent to remove an outer membrane from a surface of the phytoplankton.Type: GrantFiled: April 19, 2010Date of Patent: July 7, 2015Assignees: TOKYO INSTITUTE OF TECHNOLOGY, SUMITOMO METAL MINING CO., LTD.Inventors: Tomokazu Iyoda, Kaori Ito, Atsushi Yamada
-
Patent number: 9063034Abstract: Disclosed is a method for the determination of the absence or presence of bacillus cereus enterotoxin in a protein sample via a western blot.Type: GrantFiled: October 17, 2012Date of Patent: June 23, 2015Assignee: Scientific Protein Laboratories, LLCInventors: Dustin Nielsen, Rachel Wezeman, Matthew Bristol, Mark Eifler, Lisa Petersen, Erik Walke, Lin Rao
-
Patent number: 9028844Abstract: The present invention relates to a vaccine against Trypanosoma cruzi infection, useful in the prevention and/or treatment of the Chagas disease. More specifically, the present invention relates to a recombinant mutant trans-sialidase enzyme that can be used as an efficient vaccine, without side effects.Type: GrantFiled: March 14, 2007Date of Patent: May 12, 2015Assignees: VIB VZW, Universiteit GentInventors: Roland Contreras, Kristof De Vusser, Silvia Revelli
-
Patent number: 9018360Abstract: The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and replacement selected from the group consisting of: 1) replacement of the 36th serine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 2) replacement of the 80th tryptophan residue of SEQ ID NO: 2 with a hydrophilic amino acid residue; 3) replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 4) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 78th threonine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 5) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid thatType: GrantFiled: June 24, 2009Date of Patent: April 28, 2015Assignee: Japan Tobacco Inc.Inventors: Yoshimitsu Takakura, Masako Tsunashima, Kozue Sofuku
-
Patent number: 9017953Abstract: The present invention encompasses methods and compositions for detecting pathogenic bacteria. Additionally, the present invention encompasses methods and compositions for catalyzing the dismutation of superoxide radicals.Type: GrantFiled: May 20, 2013Date of Patent: April 28, 2015Assignee: Washington UniversityInventors: Jeffrey P. Henderson, Chia Hung, Kaveri Chaturvedi
-
Patent number: 9017956Abstract: Provided herein are uses of genes for HOG, Ras and cAMP signal transduction pathways to treat fungal infection. To regulate the HOG pathway of Cryptococcus neoformans, roles of SSK1, TCO2, SSK2, PBS2, HOG1, ENA1 and NHA1 genes were investigated to find that a biosynthesis level of ergosterol is increased when these genes are inhibited. When the genes are inhibited, a large amount of ergosterol is distributed on a fungal cell membrane. Accordingly, since there are many working points of an ergosterol-binding antifungal agent, an efficiency of the ergosterol-binding antifungal agent can be considerably improved. To regulate the Ras and cAMP pathways of Cryptococcus neoformans, roles of RAS1, RAS2, CDC24, GPA1, CAC1, ACA1, PKA1, HSP12 and HSP122 genes were investigated to find that a sensitivity to a polyene- or azole-based drug is increased when these genes are inhibited.Type: GrantFiled: April 15, 2013Date of Patent: April 28, 2015Assignee: Nutrex Technology Co., Ltd.Inventors: Yong-Sun Bahn, Young-Joon Ko, Shin-Ae Maeng, Kwang Woo Jung, Gyu Bum Kim
-
Patent number: 9005622Abstract: The present invention relates to enterococcal cell wall components and their uses in the prevention and therapy of bacterial infection.Type: GrantFiled: January 19, 2010Date of Patent: April 14, 2015Assignees: Forschungszentrum Borstel, Universitätsklinikum FreiburgInventors: Johannes Hübner, Christian Theilacker, Otto Holst, Zbigniew Kaczynski
-
Patent number: 8992935Abstract: The present invention relates to a means of controlling infection persistence of Helicobacter pylori (H. pylori). In particular, the present invention relates to an isolated, genetically modified Helicobacter pylori comprising a functional urease, wherein the contiguous amino acid sequence between amino acid 529 and amino acid 555 of SEQ ID NO:1 is altered to produce said modified Helicobacter pylori which is unable to establish or maintain a persistent infection.Type: GrantFiled: June 24, 2011Date of Patent: March 31, 2015Assignee: Ondek Pty. Ltd.Inventors: Mohammed Benghezal, Tobias Schoep, Alma Fulurija, Douglas E. Berg, Barry J. Marshall
-
Patent number: 8986704Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.Type: GrantFiled: March 14, 2013Date of Patent: March 24, 2015Assignee: Valneva Austria GmbHInventors: Pär Comstedt, Markus Hanner, Urban Lundberg, Andreas Meinke, Wolfgang Schueler, Benjamin Wizel
-
Patent number: 8986703Abstract: Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from: the polypeptide sequences of SEQ ID 1-44 or sub-sequences from these sequences, the sub-sequences having 7 amino acids or more; or from polypeptide sequences having 85% homology or more with one or more of the above sequences and contained in one or more of the following databases: GenBank, Protein Data Bank (PDB), SwissProt, Protein Information Resource (PIR), Protein Research Foundation (PRF), or CDS translations of these.Type: GrantFiled: September 5, 2008Date of Patent: March 24, 2015Assignee: PepTcell, Ltd.Inventors: Gregory Alan Stoloff, Wilson Romero Caparros-Wanderley
-
Patent number: 8980278Abstract: The present invention is directed to a bio-functionalized stimulus-responsive dissolvable PEG-hydrogel. This inventive stimulus-responsive dissolvable PEG-hydrogel comprises a matrix of PEG-polymers, which are modified to contain at least one multifunctional fusion protein, the multifunctional fusion protein preferably comprising as components a substrate binding peptide (SBP), preferably a repetitive RGD-binding peptide and/or a ZZ-binding domain, preferably a tag for purification, and at least one N- and/or C-terminal linker. The present invention is furthermore directed to the use of such inventive stimulus-responsive dissolvable PEG-hydrogels in the treatment of lesions, in surgical dressings, for wound treating, for soft and hard tissue regeneration, for the treatment of wounds in the oral cavity, in the field of ophthalmology, in the field of periodontal defects, etc. The invention also describes a method of treatment for such diseases.Type: GrantFiled: November 18, 2011Date of Patent: March 17, 2015Assignees: Universitaetsklinikum Freiburg, Albert-Ludwigs-Universitaet FreigburgInventors: Thorsten Steinberg, Wilfried Weber, Raphael Guebeli, Pascal Tomakidi, Dougal Laird
-
Patent number: 8980279Abstract: The invention provides methods of treating inflammation in a specific organ or tissue of an individual. The method involves determining whether the individual has previously been infected with at least one pathogen that is pathogenic in the specific organ or tissue; and administering to the individual an anti-inflammatory composition comprising antigenic determinants, the antigenic determinants selected or formulated so that together they are specific for the at least one pathogen. The pathogen may be an endogenous or exogenous pathogen, and may further be a bacterial pathogen, a viral pathogen, a fungal pathogen, a protozoan pathogen, or a helminth pathogen.Type: GrantFiled: July 27, 2012Date of Patent: March 17, 2015Assignee: Qu BiologicsInventors: Harold David Gunn, Salim Dhanji, Brett Anthony Premack, Michael Tak Huai Chow
-
Patent number: 8932825Abstract: The present invention relates to host cells having modified lipid-linked oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar transporters and mannosidases to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells have a GlcNAcMan3GlcNAc2 core structure which may then be modified further by heterologous expression of one or more enzymes, e.g., glycosyl-transferases, sugar transporters and mannosidases, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.Type: GrantFiled: December 24, 2002Date of Patent: January 13, 2015Assignee: GlycoFi Inc.Inventors: Stefan Wildt, Robert Gordon Miele, Juergen Hermann Nett, Robert C. Davidson
-
Patent number: 8921060Abstract: The invention relates to the area of health-beneficial preparations and production methods thereof, in particular to the use of thermally pre-treated Lactobacillus preparations having specific bonding capacity for Streptococcus mutans for caries prophylaxis. The invention further relates to the Lactobacillus preparations and thermal pasteurization.Type: GrantFiled: October 11, 2010Date of Patent: December 30, 2014Assignee: BASF SEInventor: Bryan Cooper
-
Patent number: 8889120Abstract: A method for producing bacteria belonging to the genus Bifidobacterium having excellent viability even under various conditions with different environmental factors, novel bacteria belonging to the genus Bifidobacterium obtained by the method, and a method for detecting the bacteria are provided. By subculturing and storing bacteria belonging to the genus Bifidobacterium alternately in systems under conditions with different environmental factors, the bacteria belonging to the genus Bifidobacterium exhibiting excellent viability under all the conditions used for the alternate subculturing and storing can be produced.Type: GrantFiled: February 21, 2011Date of Patent: November 18, 2014Assignee: Kabushiki Kaisha Yakult HonshaInventors: Tomoyuki Sako, Mika Miura, Yasuhisa Shimakawa, Koji Miyazaki, Junji Fujimoto, Koichi Watanabe
-
Patent number: 8835151Abstract: Disclosed is a Thermoanaerobacter sp. bacterial strain (BKHI) isolated from a hot spring, a purified protein (bioremediase) isolated from bacterial strain BKH1, as well as concrete compositions comprising BKH1 and/or the protein, and methods of using the protein and/or composition. Also disclosed are nucleic acids encoding the protein isolated from BKHI, as well as expression vectors, host cells, cell lines, and methods for generating and purifying the bioremediase protein.Type: GrantFiled: May 17, 2013Date of Patent: September 16, 2014Assignee: Jadavpur UniversityInventors: Brajadulal Chattopadhyay, Saroj Mandal